Effects of 5HT2A Blockade in Depressed Patients with Inadequate Antidepressant Treatment Response - N/A

Eli Lilly & Company Limited0 个研究点目标入组 350 人开始时间: 2005年8月17日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- Patients must meet DSM-IV criteria for a current episode of major depression without psychotic features, as determined by clinical assessment and confirmed by semi-structured interview with the MINI at Visit 1.
•- Patients must have a history of at least one prior episode of major depression within the previous 3 years (determined by clinical history).
•- Patients should have been receiving and adequately adhering to treatment with any of the following SSRI antidepressants: sertraline, paroxetine, citalopram, or escitalopram at fixed doses of at least 150, 30, 40 or 20 mg/day, respectively, for at least 4 weeks.
•- In the judgment of the investigator, patients must be considered to have experienced insufficient antidepressant response from the ongoing SSRI treatment, and be considered unlikely to benefit from further increases in SSRI dose.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Patients with suicidal ideation are not excluded from participation in this study. If suicidal ideation is present, however, the investigator should assess its severity and the potential need for other interventions prior to enrolling the patient, and then determine whether these are compatible with study participation. Patients considered at immediate high risk for harming themselves or others are excluded from participating in this study.
•- Patients with any additional, ongoing DSM-IV Axis I condition that is considered the primary diagnosis within 6 months of Visit 1 are also excluded from participation in this study.
•- Patients who received or are currently receiving additional antidepressant, stimulant, hormonal, mood stabilizer, anxiolytic or antipsychotic treatment for augmentation of ongoing SSRI therapy of the current major depressive episode will be excluded from participation in this study.

发起方

Eli Lilly & Company Limited